Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Moderna Stock Rose Today

By Joe Tenebruso - Dec 17, 2020 at 7:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An influential committee recommended emergency authorization for the drugmaker's coronavirus vaccine.

What happened 

Shares of Moderna ( MRNA 1.74% ) climbed 5% on Thursday as the biotech progressed toward a major vaccine development milestone.

So what

Late on Thursday, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee recommended authorization of Moderna's vaccine candidate for emergency use. The advisory committee helps assure vaccines are safe for the public. The FDA isn't required to follow its recommendations, but typically does. 

A digital stock chart that rises sharply and then begins to fall.

Moderna's stock popped on Thursday. Image source: Getty Images.

If the FDA grants an emergency use authorization, Moderna could begin distributing its vaccine throughout the U.S. in the coming weeks. On Dec. 11, the U.S. government struck a deal to acquire another 100 million doses of Moderna's drug, in addition to the 100 million doses it ordered in August. 

Now what 

Moderna's vaccine candidate, mRNA-1273, has emerged as one of the most promising drugs that could potentially help end the coronavirus crisis. In a phase 3 trial, the drug demonstrated a 94.1% efficacy against COVID-19. It was also shown to be 100% effective at preventing severe forms of the disease. 

"We have been working with the U.S. Centers for Disease Control and Prevention and Operation Warp Speed to prepare for the distribution of mRNA-1273, if the FDA chooses to grant an Emergency Use Authorization," Moderna CEO Stephane Bancel said in a press release. "We look forward to getting our vaccine to people in the U.S. to help address this ongoing public health emergency."

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$306.72 (1.74%) $5.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.